Gyomor- és nyelőcsőrák: vizsgálatok itt: Portugália
12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Coimbra, Lisbon, Porto, Vila Real
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Almada, Braga, Coimbra, Guimaraes, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - No phaseTaking peopleEpinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection
- Where
- Guimarães
- Életkor
- 18 év and over
- People
- 100
- Run by
- Unidade Local de Saúde do Alto Ave, EPE
See details and how to joinNCT07920068 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Lisbon, Loures, Porto
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 1/2. fázisTaking peopleA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Where
- Braga, Lisbon
- Életkor
- 18 év and over
- People
- 248 worldwide
- Run by
- Terremoto Biosciences Inc.
See details and how to joinNCT07109726 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisNot yet taking people in PortugáliaA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Porto
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - 3. fázisTaking peopleTrial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
- Where
- Braga, Guimaraes, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 228 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-513122-27-00 - 3. fázisTaking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Braga, Guimarães, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - No phaseCsak meghívásosLuso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)
- Where
- Lisbon
- Életkor
- 18 év and over
- People
- 180
- Run by
- Unidade Local de Saúde Santa Maria
See details and how to joinNCT06862479 - 3. fázisTaking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Lisbon, Porto, Vila Real
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00 - No phaseTaking peopleSUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up
- Where
- Porto
- Életkor
- 45 év and over
- People
- 912
- Run by
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
See details and how to joinNCT04613570